Table 2.

Summary of the most important therapeutical trials targeting IL-17 in RA.

Name	Molecular target	Phase	Status	Patients	Weeks	Efficacy	Reference
Secukinumab	IL-17A	I	Completed	52	6	Supported	[70]
		II	Completed	237	16	Supported	[71]
		II	Completed	174	52	Supported	[72]
		III	Ongoing	n/a	n/a	n/a	NCT01377012
		III	Ongoing	n/a	n/a	n/a	NCT01350804
Ixekizumab	IL-17A	I	Completed	97	10	Supported	[73]
		II	Completed	448	12	Supported	[74]
Brodalumab	IL-17RA	I	Completed	40	48	Not confirmed	[75]
		II	Completed	252	12	Not confirmed	[76]

n/a: no information available.